GB2306321A - The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders - Google Patents
The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders Download PDFInfo
- Publication number
- GB2306321A GB2306321A GB9521725A GB9521725A GB2306321A GB 2306321 A GB2306321 A GB 2306321A GB 9521725 A GB9521725 A GB 9521725A GB 9521725 A GB9521725 A GB 9521725A GB 2306321 A GB2306321 A GB 2306321A
- Authority
- GB
- United Kingdom
- Prior art keywords
- catechin
- connective tissue
- treatment
- prophylaxis
- tissue disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides the use of (+)-catechin and derivatives thereof which will metabolise in vivo to yield (+)-catechin for the manufacture of a medicament for use in the treatment or prophylaxis of connective tissue disorders, eg. Marfan's Syndrome, arthritis.
Description
Medlcal Treatment
The present invention relates to the treatment of connective tissue disorders and in particular to a new medical use for (+)-catechin in the treatment of Marfan
Syndrome and related diseases.
Marfan Syndrome is a condition characterised by reduced tensile strength of the connective tissues, particularly those supporting the ocular lens, the cardiac valves, the aorta and the skeletal system. The clinical manifestations of this disease are diverse; myopia, loose joints and chest deformity, for example, being commonly observed. Generally, however, the cardiovascular system is seriously affected, often resulting in severe degeneration and dilatation of the aortic wall and incompetence of the aortic valve. If left untreated, Marfan Syndrome is fatal in a large number of patients, primarily as a result of rupture or dissection of the aorta.
The loss of mechanical strength in the connective tissue is thought to be due to defective production of components of the connective tissue matrix, primarily of fibrillin and secondarily of elastin and collagen (see for example, Kainulainen et al., PNAS, iS: 5917-5921, 1992). Defective cross-linking of collagen has been demonstrated and breakdown of the fibres through the action of enzymes e.g. collagenase may be a contributory factor. Defects in the regulation of synthesis of connective tissue components such as collagen or elastin may also be involved although this has not been conclusively demonstrated.
At present there is no totally satisfactory treatment for Marfan Syndrome; frequent patient evaluation is needed, extended regimes of ss-blockers are often required and serious cardiovascular defects have to be treated by surgical repair. Similarly, other connective tissue disorders affecting the joints, such as arthritis, are treated primarily by alleviating the symptoms, by the use of analgesics and anti-inflammatory drugs, for example.
A need therefore exists for an improved method of treating Marfan Syndrome and other connective tissue disorders, and particularly for a treatment which acts at the level of the underlying condition, i.e. at the level of the defective matrix fibres and does not merely alleviate or reduce the symptoms once the condition has manifested itself.
I have now found that the known flavonoid (+)catechin is of benefit in the treatment of connective tissue disorders. More particularly, we have found that (+)-catechin acts to render connective tissue and particularly collagen, and its related fibre elastin, more resistant invivo to the effects of the enzymes collagenase, stromelysin, and elastase, which act to degrade the collagen, fibrillin and/or elastin fibres.
Moreover, I believe that a similar defect may also be implicated in other connective tissue disorders such as arthritis.(+)-catechin may therefore be particularly useful in human and veterinary medicine for the treatment or prophylaxis of connective tissue disorders which are associated with collagen, fibrillin and/or elastin breakdown. In particular I propose the use of (+)-catechin in the treatment of Marfan Syndrome.
Furthermore, my studies have shown that a significant number of Marfan patients exhibit early osteo-arthritis suggesting that the deficiency responsible for the Marfan Syndrome may also be implicated in the pathogenesis of arthritis. I thus believe that (+)-catechin may also be of benefit in the treatment of arthritis.
In one aspect the present invention therefore provides the use of (+)-catechin and derivatives thereof which will metabolise in vivo to yield (+)-catechin for the manufacture of a medicament for use in the treatment or prophylaxis of connective tissue disorders, and particularly those associated with collagen, fibrillin and/or elastin breakdown.
In a further aspect the invention provides a method of treatment of the human or animal body to combat connective tissue disorders, and particularly with those associated with collagen, fibrillin and/or elastin breakdown, said method comprising administering an effective amount of (+)-catechin or a derivative thereof as defined above, to said body.
In another aspect the invention provides the use of (+)-Catechin for the treatment or prophylaxis of connective tissue disorders, and particularly with those associated with collagen, fibrillin and/or elastin breakdown.
(+)-Catechin (trans-2-(3,4-dihydroxyphenyl)-3,4dihydro-2H-l-benzopyran, 3,5,7-triol) is a known compound described by Hardeggar aL 1, in Helv.Chim.Acta 40, 1819 (1957). It may be commercially obtained from
ZYMA.S.A. of Nyon, Switzerland. Moreover (+)-catechin may be extracted from various plant species using conventional extraction techniques (Perkin and
Yoshitake, J.Chem.Soc. 81, 116-69 (1902)).
GB-A-1341794 describes the use of (+)-catechin in the treatment of various hepatic disorders, but no mention of the therapeutic effects on connective tissue is made. The efficacy of (+)-catechin as a hepatic drug has been attributed to its activity firstly as a free radical scavenger and secondly in stimulating the immune system. These actions are not thought to be important and appear entirely unrelated to the effects of (+)catechin on connective tissue.
It is preferable to employ (+)-catechin according to the present invention in the form of a pharmaceutical formulation.
The present invention therefore also provides a pharmaceutical composition for use in the treatment of connective tissue disorders, and particularly with those associated with collagen, fibrillin and/or elastin breakdown, said composition comprising (+)-catechin together with at least one pharmaceutically acceptable carrier or excipient.
Pharmaceutical compositions for use according to the present invention may be formulated in conventional manner, for example as described in GB-A-1341794. Thus the (+)-catechin may be incorporated, optionally together with other active substances, with one or more conventional carriers and/or diluents, e.g., with cornstarch, lactose, glucose, magnesium, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, carboxymethylcellulose, or fatty substances such as hard fat or suitable mixtures thereof to produce conventional galenic preparations such as tablets, coated tablets, capsules, powders, suspensions, drops, ampoules, syrups or suppositories.
The precise dosage of the (+)-catechin to be administered and the length of the course of treatment will, of course, depend on a number of factors including, for example, the age and weight of the patient, the specific condition requiring treatment and its severity, and the route of administration.
Generally, however, an effective daily dose is in the range of 1 to 3g, preferably 1.5g administered orally, parenterally or rectally 1 to 3 times, preferably 3 times a day.
The following non-limiting Example illustrates a pharmaceutical formulation suitable for use according to the invention.
EXAMPLE 1 500mg tablet (diameter 10.5 mm) comprising 250mg (+)catechin: (+)-Catechin 250 mg
Wheat Starch 25 mg
Colloidal silicon dioxide 10 mg
Microcrystalline cellulose 100 mg
Lactose 105 mg talc 10 mg
500 mg
Claims (5)
- CLAIMS: 1. The use of (+)-catechin and derivatives thereof which will metabolise in vivo to yield (+)-catechin for the manufacture of a medicament for use in the treatment or prophylaxis of connective tissue disorders in humans or animals.
- 2. The use as claimed in claim 1 wherein said connective tissue disorder is associated with collagen, fibrillin and/or elastin breakdown.
- 3. The use as claimed in either claim 1 or claim 2 wherein said connective tissue disorder is Marfan Syndrome.
- 4. The use as claimed in claim 1 wherein said connective tissue disorder is arthritis.
- 5. The use as claimed in any one of claims 1 to 4 wherein said medicament is in a form suitable for administration orally, parenterally or rectally.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9521725A GB2306321A (en) | 1995-10-24 | 1995-10-24 | The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9521725A GB2306321A (en) | 1995-10-24 | 1995-10-24 | The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9521725D0 GB9521725D0 (en) | 1996-01-03 |
GB2306321A true GB2306321A (en) | 1997-05-07 |
Family
ID=10782794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9521725A Withdrawn GB2306321A (en) | 1995-10-24 | 1995-10-24 | The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2306321A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000074662A2 (en) * | 1999-06-07 | 2000-12-14 | University Of Sheffield | Arthritis treatment |
EP1490081A4 (en) * | 2002-03-22 | 2006-04-12 | Unigen Pharmaceuticals Inc | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
US7514469B2 (en) * | 2002-04-30 | 2009-04-07 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
US7695743B2 (en) | 2002-04-30 | 2010-04-13 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US8790724B2 (en) | 2003-04-04 | 2014-07-29 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
WO2014184198A1 (en) * | 2013-05-17 | 2014-11-20 | Valore | Oral composition comprising (+)-catechin |
US8945518B2 (en) | 2002-04-30 | 2015-02-03 | Unigen, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2057437A (en) * | 1979-08-30 | 1981-04-01 | Continental Pharma | Salts of (+)-catechin their preparation and use and compositions and formulations containing them |
US4268517A (en) * | 1979-08-30 | 1981-05-19 | Continental Pharma | Pharmaceutical composition and therapeutical method for treating degenerative affections of the articular cartilage |
-
1995
- 1995-10-24 GB GB9521725A patent/GB2306321A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2057437A (en) * | 1979-08-30 | 1981-04-01 | Continental Pharma | Salts of (+)-catechin their preparation and use and compositions and formulations containing them |
US4268517A (en) * | 1979-08-30 | 1981-05-19 | Continental Pharma | Pharmaceutical composition and therapeutical method for treating degenerative affections of the articular cartilage |
Non-Patent Citations (5)
Title |
---|
Experientia (1976), 32(6), p.691-93 * |
Ital.J.Biochem., (1981), 30(1), p.54-62 * |
Leather Sci. (Madras) (1979), 26(8), p.285-94 * |
Scand.J.Rheumatol., (1983), 12(1), p.39-42 * |
Scand.J.Rheumatol.,(1978), 7(1), p.55-60 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000074662A3 (en) * | 1999-06-07 | 2002-03-14 | Univ Sheffield | Arthritis treatment |
WO2000074662A2 (en) * | 1999-06-07 | 2000-12-14 | University Of Sheffield | Arthritis treatment |
US8124134B2 (en) | 2002-03-22 | 2012-02-28 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia |
EP1490081A4 (en) * | 2002-03-22 | 2006-04-12 | Unigen Pharmaceuticals Inc | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
US9168242B2 (en) | 2002-03-22 | 2015-10-27 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipdxygenase inhibitor from Acacia |
US8568799B2 (en) | 2002-03-22 | 2013-10-29 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from acacia |
US7695743B2 (en) | 2002-04-30 | 2010-04-13 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US8034387B2 (en) | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US8652535B2 (en) | 2002-04-30 | 2014-02-18 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US8945518B2 (en) | 2002-04-30 | 2015-02-03 | Unigen, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
US7514469B2 (en) * | 2002-04-30 | 2009-04-07 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
US9370544B2 (en) | 2002-04-30 | 2016-06-21 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
US9655940B2 (en) | 2002-04-30 | 2017-05-23 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
US9849152B2 (en) | 2002-04-30 | 2017-12-26 | Unigen, Inc. | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
US8790724B2 (en) | 2003-04-04 | 2014-07-29 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
US9622964B2 (en) | 2003-04-04 | 2017-04-18 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
WO2014184198A1 (en) * | 2013-05-17 | 2014-11-20 | Valore | Oral composition comprising (+)-catechin |
US9844595B2 (en) | 2013-05-17 | 2017-12-19 | Valore | Composition comprising a complex of (+)-catechin and amino acid for the treatment and prevention of cancer |
Also Published As
Publication number | Publication date |
---|---|
GB9521725D0 (en) | 1996-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5849740A (en) | Methods for using ketoconazole and related substances in medicaments for treatment of type II diabetes | |
IE66527B1 (en) | Bilobalide for use as a therapeutic substance | |
US20080166420A1 (en) | Krill Oil Compositions | |
US11826345B2 (en) | Dosing regimens of PKC activators | |
WO2014016003A1 (en) | Use of biotin for the treatment of multiple sclerosis | |
WO2015152416A1 (en) | Ocular hypotensive agent | |
JPH0920659A (en) | Kappa opium preparation agonist for inflammatory abdominal disease | |
HU203198B (en) | Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect | |
JPH02180820A (en) | Acetyl-l-carnitine cataract treating agent | |
US20080166419A1 (en) | Krill oil compositions | |
US20060235009A1 (en) | Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors | |
GB2306321A (en) | The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders | |
WO2022094370A1 (en) | Methods of treating and preventing neurodegenerative diseases with hgf activating compounds | |
WO2024022468A1 (en) | Use of rhamnose in preparing medicament for treating or preventing neurodegenerative diseases, pharmaceutical composition, and use thereof | |
US5665769A (en) | Pharmaceutical composition for preventing and treating retinal diseases | |
WO2006065793A9 (en) | TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS | |
WO2006043260A2 (en) | Orally effective cannabinoid analogs | |
JP4039482B2 (en) | Use of cortisol antagonists for the treatment of heart disease | |
US4906649A (en) | Use of a compound for the treatment of sleep disorders and depression | |
KR100851938B1 (en) | Kapp-opiate agonists for the treatment of bladder dieseases | |
JP2018512451A (en) | Biotin for the treatment of amyotrophic lateral sclerosis | |
US20230000943A1 (en) | Method of inducing synaptogenesis by administering angiotensin and analogues thereof | |
JP4972156B2 (en) | N- (dibenzo (b, f) oxepin-10-ylmethyl) N-methyl-N-prop-2-ynylamine (Omigapyr) for prevention and / or treatment of congenital muscular dystrophy or myopathy caused by type VI collagen deficiency Usage | |
CA3078609A1 (en) | The use of a benzoate containing composition to treat glycine encephalopathy | |
KR20190005158A (en) | And compositions for the treatment of LET's syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |